Skip to content

Late Infantile Neuronal Ceroid Lipofuscinosis 6 C5880894

Published: July 22, 2026Updated: August 25, 2026

A form of Batten disease causing progressive nerve cell loss in children, leading to seizures and developmental decline. Affects children. Fatal.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
G31.82
ICD-11
8A00.0
Body system
neurologic
Severity
fatal
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Generalized symptoms

Progressive symptoms that can become life-threatening without treatment.

Seek immediate medical attention if symptoms worsen.

!

Seizures

Myoclonus

(neurologic)

Ataxia

(neurologic)

Dementia

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Comprehensive seizure management

Given the progressive nature of NCL-6, proactive seizure management with appropriate anticonvulsants is a cornerstone of care to minimize seizure-related complications and maintain quality of life.

medication
2

Standard interventional procedure protocol

Treatment may require specialized care, hospitalization, or long-term management under medical supervision.

procedure
3

Gastrostomy tube placement

When oral intake becomes insufficient or unsafe due to swallowing difficulties, percutaneous endoscopic gastrostomy provides reliable nutrition and hydration while reducing aspiration risk.

surgical

Additional treatment options

Motor function preservation therapy

Aggressive physical therapy intervention aims to preserve ambulation, maintain joint mobility, and prevent secondary complications from immobility for as long as possible.

physical_therapy

Vision support and environmental adaptations

Vision loss is a prominent feature; environmental modifications, tactile stimulation, and sensory integration activities help maintain quality of life and communication abilities.

complementary

Cardiorespiratory monitoring

Regular cardiac and respiratory monitoring is recommended as autonomic dysfunction can develop, particularly during sleep.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Late Infantile Neuronal Ceroid Lipofuscinosis 6 C5880894?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Mole SE, Schulz A, Badoe E, et al. Guidelines on the diagnosis, clinical management and therapeutic interventions for neuronal ceroid lipofuscinosis type 2 (CLN2) disease and other neuronal ceroid lipofuscinoses. Orphanet J Rare Dis. 2021.

guideline2021
2

Kohan R, Pesa E, Cismondi IA, Dodelson de Kremer R. Evidence of genotype-phenotype correlation in CLN6-related neuronal ceroid lipofuscinosis. Mol Genet Metab. 2020.

review2020
3

Sano T, Koyano F, Miyake N, et al. Long-term follow-up of patients with variant late infantile neuronal ceroid lipofuscinosis 6. J Child Neurol. 2019.

clinical_trial2019
4

Johnson TB, Cain JT, White KA, et al. Therapeutic landscape for neuronal ceroid lipofuscinosis: molecular mechanisms and clinical trials. Neurobiol Dis. 2022.

review2022

Medication Comparisons

Compare medications used to treat Late Infantile Neuronal Ceroid Lipofuscinosis 6 C5880894. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy